Pros
I worked with some very smart, pleasant coworkers at CareDX. Also, management was reasonable about allowing PTO and providing decent work life balance. The Brisbane facilities are in good condition and are in a nice area—you have ample parking and options for walks and good food on your breaks. Depending on when you started you might have made a lot of money on stock RSUs and bonuses in the past, so overall pay was above industry standard for many. If you started recently you may not have witnessed this as much. If you managed to get along with management there were some decent growth opportunities in this company. Allomap and Allosure still manage to provide tens of millions per quarter in revenue consistently.
Cons
The prognosis for this company is now fairly poor. There has been setback after setback. CareDX lost a patent dispute with Natera. Medicare recently significantly cut reimbursement for products cutting sample volume significantly. There is still open government investigations into billing issues. The CEO went on record saying the company would get “leaner” though layoffs likely won’t apply to every department. After dumping tens of millions into R&D this company failed to come up with good products in the last few years. Automation upgrades are coming but are slow. The IT system is in particular poor. Training in this company is slow, and is nonexistent for people management doesn’t like. Like many molecular laboratories CLIA staff is at risk for repetitive stress injuries. This is particularly serious in one of the assays management failed to automate. Multiple people developed serious injuries. Some issues with payroll paying people correctly. Double check paychecks. Upper management is all sales based. They know little of the transplant products they market and have led research teams into dead ends through inexperience. Much of this group that seems to be always working from home needs to be replaced completely if this company can survive the setbacks it is facing.